Stock-based compensation

6 Months Ended

Jun. 30, 2020

Stockholders' Equity Note [Abstract]

During the six months ended June 30, 2020, the Company granted stock options to purchase 0.4 million shares of common stock and 0.8 million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the three months ended June 30, 2020, the Company issued a broad-based fully vested equity award of approximately 0.2 million shares to employees below the senior vice president level that was valued at $14.7 million and is recorded as share-based compensation expense for the period ended June 30, 2020.

Stock-based compensation expense was recorded in the following financial statement line items:



	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Cost of product sales and contract development and manufacturing services	$	8.1	$	0.6	$	8.8	$	1.4
Research and development	5.4		1.0		6.3		2.1
Selling, general and administrative	10.9		6.5		15.9		11.4
Total stock-based compensation expense	$	24.4	$	8.1	$	31.0	$	14.9